Kornek G - Search Results

1

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.

Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. Wirth LJ, et al. Among authors: kornek g. Oral Oncol. 2016 Oct;61:31-40. doi: 10.1016/j.oraloncology.2016.07.005. Epub 2016 Aug 20. Oral Oncol. 2016. PMID: 27688102 Clinical Trial.

2

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T. Haddad R, et al. Among authors: kornek g. Oral Oncol. 2019 Oct;97:82-91. doi: 10.1016/j.oraloncology.2019.08.004. Epub 2019 Aug 23. Oral Oncol. 2019. PMID: 31450171 Clinical Trial.

3

Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Gedlicka C, Formanek M, Selzer E, Burian M, Kornfehl J, Fiebiger W, Cartellieri M, Marks B, Kornek GV. Gedlicka C, et al. Among authors: kornek gv. Oncology. 2002;63(2):145-50. doi: 10.1159/000063809. Oncology. 2002. PMID: 12239449 Clinical Trial.

4

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.

Fuchs H, Pammer J, Minichsdorfer C, Posch D, Kornek G, Aretin MB, Fuereder T. Fuchs H, et al. Among authors: kornek g. Med Oncol. 2018 Feb 7;35(3):32. doi: 10.1007/s12032-018-1087-6. Med Oncol. 2018. PMID: 29411154 Free PMC article.

5

Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer.

Schüll B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F, Scheithauer W. Schüll B, et al. Oncology. 2003;65(3):211-7. doi: 10.1159/000074473. Oncology. 2003. PMID: 14657594 Clinical Trial.

6

Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Vormittag L, Lemaire C, Radonjic D, Kornek G, Selzer E. Vormittag L, et al. Among authors: kornek g. Strahlenther Onkol. 2012 Mar;188(3):235-42. doi: 10.1007/s00066-011-0040-9. Epub 2012 Feb 10. Strahlenther Onkol. 2012. PMID: 22318328 Clinical Trial.

7

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Posch D, Fuchs H, Kornek G, Grah A, Pammer J, Aretin MB, Fuereder T. Posch D, et al. Among authors: kornek g. Sci Rep. 2016 Sep 6;6:32946. doi: 10.1038/srep32946. Sci Rep. 2016. PMID: 27597175 Free PMC article. Clinical Trial.

8

Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma.

Hejna M, Kornek GV, Raderer M, Marosi L, Schneeweiss B, Greul R, Weinländer G, Valencak J, Huber H, Scheithauer W. Hejna M, et al. Among authors: kornek gv. Oncology. 1998 Nov-Dec;55(6):538-42. doi: 10.1159/000011909. Oncology. 1998. PMID: 9778620 Clinical Trial.

9

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.

Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G. Keil F, et al. Among authors: kornek g. Eur J Cancer. 2013 Jan;49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14. Eur J Cancer. 2013. PMID: 22981499 Clinical Trial.

10

Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.

Russmueller G, Moser D, Würger T, Wrba F, Christopoulos P, Kostakis G, Seemann R, Stadler V, Wimmer G, Kornek G, Psyrri A, Filipits M, Perisanidis C. Russmueller G, et al. Among authors: kornek g. Oral Oncol. 2015 Mar;51(3):247-53. doi: 10.1016/j.oraloncology.2014.11.010. Epub 2014 Dec 17. Oral Oncol. 2015. PMID: 25532817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters